Your browser doesn't support javascript.
loading
NTAL is associated with treatment outcome, cell proliferation and differentiation in acute promyelocytic leukemia.
Thomé, Carolina Hassibe; Ferreira, Germano Aguiar; Pereira-Martins, Diego Antonio; Dos Santos, Guilherme Augusto; Ortiz, César Alexander; de Souza, Lucas Eduardo Botelho; Sobral, Lays Martins; Silva, Cleide Lúcia Araújo; Scheucher, Priscila Santos; Gil, Cristiane Damas; Leopoldino, Andréia Machado; Silveira, Douglas R A; Coelho-Silva, Juan L; Traina, Fabíola; Koury, Luisa C; Melo, Raul A M; Bittencourt, Rosane; Pagnano, Katia; Pasquini, Ricardo; Nunes, Elenaide C; Fagundes, Evandro M; Gloria, Ana Beatriz F; Kerbauy, Fábio Rodrigues; Chauffaille, Maria de Lourdes; Keating, Armand; Tallman, Martin S; Ribeiro, Raul C; Dillon, Richard; Ganser, Arnold; Löwenberg, Bob; Valk, Peter; Lo-Coco, Francesco; Sanz, Miguel A; Berliner, Nancy; Faça, Vitor Marcel; Rego, Eduardo M.
Affiliation
  • Thomé CH; Department of Biochemistry and Immunology, Medical School of Ribeirão Preto, University of São Paulo, Ribeirão Preto, Brazil.
  • Ferreira GA; Regional Blood Center of Ribeirão Preto, Medical School of Ribeirão Preto, Center for Cell Based Therapy, University of São Paulo, Ribeirão Preto, Brazil.
  • Pereira-Martins DA; Department of Biochemistry and Immunology, Medical School of Ribeirão Preto, University of São Paulo, Ribeirão Preto, Brazil.
  • Dos Santos GA; Regional Blood Center of Ribeirão Preto, Medical School of Ribeirão Preto, Center for Cell Based Therapy, University of São Paulo, Ribeirão Preto, Brazil.
  • Ortiz CA; Regional Blood Center of Ribeirão Preto, Medical School of Ribeirão Preto, Center for Cell Based Therapy, University of São Paulo, Ribeirão Preto, Brazil.
  • de Souza LEB; Regional Blood Center of Ribeirão Preto, Medical School of Ribeirão Preto, Center for Cell Based Therapy, University of São Paulo, Ribeirão Preto, Brazil.
  • Sobral LM; Regional Blood Center of Ribeirão Preto, Medical School of Ribeirão Preto, Center for Cell Based Therapy, University of São Paulo, Ribeirão Preto, Brazil.
  • Silva CLA; Regional Blood Center of Ribeirão Preto, Medical School of Ribeirão Preto, Center for Cell Based Therapy, University of São Paulo, Ribeirão Preto, Brazil.
  • Scheucher PS; Department of Clinical Analyses, Toxicology and Food Sciences, University of São Paulo, Ribeirão Preto, Brazil.
  • Gil CD; Regional Blood Center of Ribeirão Preto, Medical School of Ribeirão Preto, Center for Cell Based Therapy, University of São Paulo, Ribeirão Preto, Brazil.
  • Leopoldino AM; Regional Blood Center of Ribeirão Preto, Medical School of Ribeirão Preto, Center for Cell Based Therapy, University of São Paulo, Ribeirão Preto, Brazil.
  • Silveira DRA; Department of Morphology and Genetics, Federal University of São Paulo, São Paulo, Brazil.
  • Coelho-Silva JL; Department of Clinical Analyses, Toxicology and Food Sciences, University of São Paulo, Ribeirão Preto, Brazil.
  • Traina F; Hematology, Medical School, University of São Paulo, São Paulo, Brazil.
  • Koury LC; Regional Blood Center of Ribeirão Preto, Medical School of Ribeirão Preto, Center for Cell Based Therapy, University of São Paulo, Ribeirão Preto, Brazil.
  • Melo RAM; Regional Blood Center of Ribeirão Preto, Medical School of Ribeirão Preto, Center for Cell Based Therapy, University of São Paulo, Ribeirão Preto, Brazil.
  • Bittencourt R; Regional Blood Center of Ribeirão Preto, Medical School of Ribeirão Preto, Center for Cell Based Therapy, University of São Paulo, Ribeirão Preto, Brazil.
  • Pagnano K; Department of Internal Medicine, University of Pernambuco, Recife, Brazil.
  • Pasquini R; Hematology Division, Federal University of Rio Grande do Sul, Porto Alegre, Brazil.
  • Nunes EC; Hematology and Hemotherapy Center, University of Campinas, Campinas, Brazil.
  • Fagundes EM; Hematology Division, Federal University of Paraná, Curitiba, Brazil.
  • Gloria ABF; Hematology Division, Federal University of Paraná, Curitiba, Brazil.
  • Kerbauy FR; Hematology Division, Federal University of Minas Gerais, Belo Horizonte, Brazil.
  • Chauffaille ML; Hematology Division, Federal University of Minas Gerais, Belo Horizonte, Brazil.
  • Keating A; Federal University of São Paulo, São Paulo, Brazil.
  • Tallman MS; Federal University of São Paulo, São Paulo, Brazil.
  • Ribeiro RC; Cell Therapy Program, Princess Margaret Cancer Centre, Toronto, Canada.
  • Dillon R; Leukemia Service, Memorial Sloan-Kettering Cancer Center/Weill Cornell Medical College, New York, USA.
  • Ganser A; Department of Oncology, St. Jude Children's Research Hospital, Memphis, USA.
  • Löwenberg B; Department of Medical and Molecular Genetics, King's College London School of Medicine, London, UK.
  • Valk P; Department of Hematology, Hemostasis, Oncology, and Stem Cell Transplantation, Hannover Medical School, Hannover, Germany.
  • Lo-Coco F; Department of Hematology, Erasmus University Medical Center, Rotterdam, Netherlands.
  • Sanz MA; Santa Lucia Foundation, Rome, Italy.
  • Berliner N; Department of Biopathology, Tor Vergata University, Rome, Italy.
  • Faça VM; Santa Lucia Foundation, Rome, Italy.
  • Rego EM; Department of Hematology, Valencia University Medical School, Valencia, Spain.
Sci Rep ; 10(1): 10315, 2020 06 25.
Article in En | MEDLINE | ID: mdl-32587277
ABSTRACT
Non-T cell activation linker (NTAL) is a lipid raft-membrane protein expressed by normal and leukemic cells and involved in cell signaling. In acute promyelocytic leukemia (APL), NTAL depletion from lipid rafts decreases cell viability through regulation of the Akt/PI3K pathway. The role of NTAL in APL cell processes, and its association with clinical outcome, has not, however, been established. Here, we show that reduced levels of NTAL were associated with increased all-trans retinoic acid (ATRA)-induced differentiation, generation of reactive oxygen species, and mitochondrial dysfunction. Additionally, NTAL-knockdown (NTAL-KD) in APL cell lines led to activation of Ras, inhibition of Akt/mTOR pathways, and increased expression of autophagy markers, leading to an increased apoptosis rate following arsenic trioxide treatment. Furthermore, NTAL-KD in NB4 cells decreased the tumor burden in (NOD scid gamma) NSG mice, suggesting its implication in tumor growth. A retrospective analysis of NTAL expression in a cohort of patients treated with ATRA and anthracyclines, revealed that NTAL overexpression was associated with a high leukocyte count (P = 0.007) and was independently associated with shorter overall survival (Hazard Ratio 3.6; 95% Confidence Interval 1.17-11.28; P = 0.026). Taken together, our data highlights the importance of NTAL in APL cell survival and response to treatment.
Subject(s)

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Leukemia, Promyelocytic, Acute / Antineoplastic Combined Chemotherapy Protocols / Adaptor Proteins, Signal Transducing Type of study: Observational_studies / Risk_factors_studies Language: En Journal: Sci Rep Year: 2020 Document type: Article Affiliation country: Brazil

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Leukemia, Promyelocytic, Acute / Antineoplastic Combined Chemotherapy Protocols / Adaptor Proteins, Signal Transducing Type of study: Observational_studies / Risk_factors_studies Language: En Journal: Sci Rep Year: 2020 Document type: Article Affiliation country: Brazil